XML 45 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Interim Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended 190 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Cash flows (used in): Operating activities:          
Net (loss)/income $ (602) $ (348) $ 2,112 $ 4,321 $ (101,858)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization 0 0 0 0 1,404
Non-cash Cadherin Biomedical Inc. litigation 0 0 0 0 1,187
Unrealized(gain) on derivative (645) (225) (3,971) (5,905) (8,792)
Amortization of deferred lease inducements 0 0 0 0 (412)
Unrealized foreign exchange loss 0 (13) 0 (3) 36
Loss on impairment of capital assets 0 0 0 0 386
Non-cash severance 0 0 0 0 168
Stock-based compensation - consultants 35 49 35 49 931
Stock-based compensation - employees 17 0 17 0 10,112
Acquired in-process research and development 0 0 0 0 13,094
Changes in operating assets and liabilities 62 2,309 96 (285) (10)
Net cash used in operating activities (1,133) 1,772 (1,711) (1,823) (83,754)
Investing activities:          
Purchase of capital assets 0 0 0 0 (1,440)
Disposal of capital assets 0 0 0 0 115
Proceeds from sale of assets 0 0 0 0 24
Release of restricted cash 0 0 0 0 190
Restricted cash 0 0 0 0 (209)
Purchase of short-term investments 0 0 0 0 (22,148)
Redemption of short-term investments 0 0 0 0 22,791
Investment in Cadherin Biomedical Inc. 0 0 0 0 (166)
Acquired intellectual property rights 0 0 0 0 (640)
Net cash used in investing activities 0 0 0 0 (1,483)
Financing activities:          
Conversion of long-term debt to equity 0 0 0 0 68
Long-term debt repayment 0 0 0 0 (65)
Capital lease repayments 0 0 0 0 (8)
Issuance of units, net of issue costs 0 0 0 2,566 86,443
Registration expense 0 0 0 0 (465)
Proceeds from convertible note 0 0 0 0 3,017
Other liability repayments 0 0 0 0 (87)
Financing expenses 0 0 0 0 (544)
Security deposits received 0 0 0 0 35
Proceeds from exercise of stock options 0 0 0 0 51
Net cash provided by financing activities 0 0 0 2,566 88,445
Effect of exchange rate on cash and cash equivalents 0 15   139 378
(Decrease)/Increase in cash and cash equivalents (1,133) 1,787 (1,711) 882 3,586
Cash and cash equivalents - Beginning of period 4,719 5,023 5,297 5,947 0
Cash and cash equivalents - End of period $ 3,586 $ 6,810 $ 3,586 $ 6,810 $ 3,586